Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor ...

Retrieved on: 2021-04-19 09:33:45

Tags for this article:

Click the tags to see associated articles and topics

Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor .... View article details on hiswai:

Excerpt

EVT801 also has marked activity on the immune system within the tumour and may therefore enhance the activity of immuno-oncology therapies.

Article found on: www.biospace.com